Citius Pharmaceuticals price target lowered to $4 from $6 at H.C. Wainwright

H.C. Wainwright analyst Vernon Bernardino lowered the firm’s price target on Citius Pharmaceuticals to $4 from $6 and keeps a Buy rating on the shares. The Complete Response Letter does not indicate Lymphir is not approvable, the analyst tells investors in a research note. The firm now expects Lymphir approval in cutaneous T-cell lymphoma in early 2024.